SS Innovations Announces World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra Surgical Robotic System
SS Innovations showcases a world-first dual-console robotic heart surgery in India.
What the company is saying
SS Innovations International, Inc. is highlighting the successful completion of the world’s first dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (TECAB) surgery using all five arms of its SSi Mantra robotic system. The announcement emphasizes the technical and clinical achievement, naming Dr. Nitin Kumar Rajput and Dr. Lalit Malik as the surgeons, with oversight from Dr. Sudhir Srivastava, the company’s Chairman and CEO. The company frames this as a landmark for minimally invasive cardiac surgery, stressing the advanced capabilities of the SSi Mantra system and its potential to democratize access to complex robotic procedures. The messaging is confident, with multiple executives and hospital leaders quoted to reinforce the significance of the event and the positive patient outcome. The release underscores the system’s modularity, advanced visualization, and broad clinical validation, but does not mention commercial sales, revenue, or regulatory milestones. The tone is optimistic and forward-looking, positioning the achievement as a step toward broader adoption and future transformation of cardiac surgery.
What the data suggests
The announcement provides concrete technical details: the procedure used all five robotic arms and two consoles of the SSi Mantra system in synchronized operation, marking a first in cardiac surgery. The system has been clinically validated in India across more than 190 different types of surgical procedures and supports over 40 types of robotic endo-surgical instruments, including specialized pediatric and ENT tools. The SSi Mantra system offers 3 to 5 modular arms, a 3D 4K monitor, and advanced imaging capabilities. The procedure was performed at Medanta Hospital in Gurugram, India, with the patient reportedly recovering well, though no quantitative clinical outcome data are provided. The data demonstrate technical feasibility and clinical use but do not address commercial adoption, sales, or financial performance. The evidence supports the claim of a technical milestone but does not substantiate broader market impact or financial trajectory.
Analysis
The announcement describes a genuine technical milestone: the world’s first dual-console, beating-heart TECAB surgery using all five arms of the SSi Mantra system, performed at a named hospital in India with specific surgeons and system features detailed. The majority of claims are realised and supported by operational facts (number of arms, consoles, procedures, and clinical validation in over 190 types of surgeries). However, the tone is somewhat inflated by forward-looking statements about transforming future surgery and expanding possibilities, which are not yet substantiated by commercial adoption or financial results. No revenue, profit, or commercial contract data are disclosed, so the investment impact cannot be assessed. The gap lies in the leap from a single successful procedure to broad market or financial impact, which is implied but not evidenced. There is no indication of a large capital outlay or delayed benefit; the milestone is immediate and technical.
Risk flags
- ●There is a clear gap between technical achievement and commercial adoption; the announcement does not disclose any sales, contracts, or regulatory approvals, so the pathway to revenue remains unproven.
- ●The reliance on a single high-profile procedure and quoted executive endorsements creates a risk that broader clinical acceptance or market traction may not follow without further evidence.
- ●No quantitative patient outcome data or comparative clinical results are provided, limiting the ability to assess the real-world impact or safety profile of the technology.
- ●The announcement is silent on regulatory status outside India, which could delay or complicate international commercialization.
- ●Absence of financial data, such as revenue, backlog, or order book, prevents assessment of the company’s current commercial momentum or capital requirements.
Bottom line
SS Innovations has achieved a genuine technical milestone by enabling the world’s first dual-console, beating-heart TECAB surgery using its SSi Mantra robotic system in India. The announcement is credible as a demonstration of advanced robotic capabilities, with specific details on system features and clinical validation. However, the release does not provide any financial, commercial, or regulatory progress, so the investment case remains tied to future adoption rather than current revenue or profitability. The involvement of prominent surgeons and hospital leaders adds credibility, but does not guarantee broader market uptake. For investors, the key takeaway is that SS Innovations is technically advancing in robotic surgery, but evidence of commercial traction or financial impact is still lacking. The next critical disclosures would be commercial sales figures, regulatory milestones outside India, or repeatable clinical outcomes in diverse settings.
Track record
NewsStack has analysed 3 announcements from SSII since October 2026.
Previous SSII verdicts
Announcement summary
(NASDAQ: SSII) SS Innovations International, Inc. announced that a team of surgeons successfully completed the world’s first dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (TECAB) surgery using all five arms of the Company’s SSi Mantra surgical robotic system at Medanta - The Medicity Hospital in Gurugram, India. The procedure was performed by Dr. Nitin Kumar Rajput of Medanta Hospital and Dr. Lalit Malik of Manipal Hospital, Jaipur, under the guidance of Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations. The operation utilized two separate consoles and all five robotic arms of the SSi Mantra in complete synchronization. A heart stabilization system was used to steady the target area while the patient’s heart continued to beat. This TECAB surgery was performed through small incisions without opening the chest, differing from conventional sternotomy approaches. The beating-heart method allowed the bypass to be performed without a heart-lung machine. The combination of dual-console control and a five-arm robotic configuration represents a significant advancement in minimally invasive cardiac surgery. Dr. Srivastava stated that the successful use of dual-console control and five robotic arms in a beating-heart TECAB procedure demonstrates the advanced capabilities of the SSi Mantra system. Dr. Naresh Trehan, Chairman and Managing Director of Medanta Hospital, confirmed this was the first time such a procedure had been performed in the world and reported that the patient is doing extremely well. Dr. Rajput emphasized the precision, coordination, and collaboration required for the procedure, noting the patient’s encouraging recovery. Dr. Malik highlighted the importance of the dual-console setup and five-arm configuration in supporting the technical demands of the operation. The SSi Mantra surgical robotic system is a modular, multi-arm system with 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console provides equivalent control functionality with enhanced portability and telesurgery capability. The SSi Mantra uses over 40 different types of robotic endo-surgical instruments, including 5 mm instruments for pediatric and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
Disagree with this article?
Ctrl + Enter to submit